Pneumonia, Pneumococcal Therapeutic Market 规模与份额分析 - 成长趋势与预测 (2024 - 2031)
Pneumonia, Pneumococcal Therapeutic Market is segmented By Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral, Topical), By Molecule Type (Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide Polymer, Gene Therapy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Pneumonia, Pneumococcal Therapeutic Market Size
市场规模（美元） Bn
复合年增长率8.4%
| 研究期 | 2024 - 2031 |
| 基准年 | 2023 |
| 复合年增长率 | 8.4% |
| 市场集中度 | Medium |
| 主要玩家 | Biotest AG, Vaxcyte, Inc., Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc. and Among Others. |
please let us know !
Pneumonia, Pneumococcal Therapeutic Market Analysis
The pneumonia, pneumococcal therapeutic market is estimated to be valued at USD 2.72 Billion in 2024 and is expected to reach USD 4.77 Billion by 2031, growing at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031. The growing geriatric population and increased risk of pneumonia among the elderly is driving the demand. Furthermore, rising pollution levels and environmental factors leading to higher prevalence of respiratory illnesses are also boosting the market growth.